NASDAQ:EYPT - Eyepoint Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Eyepoint Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.70 -0.01 (-0.58 %) (As of 01/20/2020 04:00 PM ET) Add Compare Today's Range$1.68Now: $1.70▼$1.8050-Day Range$1.44MA: $1.52▼$1.7152-Week Range$1.19Now: $1.70▼$2.82Volume422,961 shsAverage Volume343,250 shsMarket Capitalization$183.80 millionP/E RatioN/ADividend YieldN/ABeta1.62 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States and Europe. It provides ILUVIEN for the treatment of diabetic macular edema; YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis (NIPU) that is in the Phase III clinical trials; and Retisert (fluocinolone acetonide intravitreal implant), a sustained-release implant for the treatment of posterior segment uveitis. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Analytical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EYPT Previous Symbol CUSIPN/A CIK1314102 Webhttp://eyepointpharma.com/ Phone833-393-7646Debt Debt-to-Equity Ratio3.12 Current Ratio4.54 Quick Ratio4.29Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.96 million Price / Sales62.10 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($0.58) Net Income$-53,170,000.00 Net Margins-409.07% Return on Equity-250.32% Return on Assets-63.54%Miscellaneous Employees55 Outstanding Shares108,120,000Market Cap$183.80 million Next Earnings Date3/12/2020 (Estimated) OptionableOptionable Receive EYPT News and Ratings via Email Sign-up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:EYPT Rates by TradingView Eyepoint Pharmaceuticals (NASDAQ:EYPT) Frequently Asked Questions What is Eyepoint Pharmaceuticals' stock symbol? Eyepoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT." How were Eyepoint Pharmaceuticals' earnings last quarter? Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) released its quarterly earnings results on Thursday, November, 7th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.01. The company had revenue of $2.51 million for the quarter, compared to analyst estimates of $4.81 million. Eyepoint Pharmaceuticals had a negative return on equity of 250.32% and a negative net margin of 409.07%. View Eyepoint Pharmaceuticals' Earnings History. When is Eyepoint Pharmaceuticals' next earnings date? Eyepoint Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Eyepoint Pharmaceuticals. What price target have analysts set for EYPT? 4 Wall Street analysts have issued 1 year price targets for Eyepoint Pharmaceuticals' stock. Their forecasts range from $4.00 to $5.00. On average, they expect Eyepoint Pharmaceuticals' share price to reach $4.38 in the next year. This suggests a possible upside of 157.4% from the stock's current price. View Analyst Price Targets for Eyepoint Pharmaceuticals. What is the consensus analysts' recommendation for Eyepoint Pharmaceuticals? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyepoint Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eyepoint Pharmaceuticals. Has Eyepoint Pharmaceuticals been receiving favorable news coverage? News stories about EYPT stock have been trending somewhat positive this week, according to InfoTrie. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Eyepoint Pharmaceuticals earned a coverage optimism score of 1.7 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Eyepoint Pharmaceuticals. Are investors shorting Eyepoint Pharmaceuticals? Eyepoint Pharmaceuticals saw a drop in short interest in the month of December. As of December 31st, there was short interest totalling 8,490,000 shares, a drop of 5.5% from the December 15th total of 8,980,000 shares. Based on an average daily trading volume, of 570,600 shares, the short-interest ratio is presently 14.9 days. Approximately 13.0% of the shares of the stock are sold short. View Eyepoint Pharmaceuticals' Current Options Chain. Who are some of Eyepoint Pharmaceuticals' key competitors? Some companies that are related to Eyepoint Pharmaceuticals include Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO), Arrayit (ARYC), Precipio (PRPO), Scientific Industries (SCND), Aethlon Medical (AEMD), Pressure Biosciences (PBIO) and PositiveID (PSID). What other stocks do shareholders of Eyepoint Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eyepoint Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Synergy Pharmaceuticals (SGYP), Progenics Pharmaceuticals (PGNX), XOMA (XOMA), Opko Health (OPK), Catalyst Pharmaceuticals (CPRX), AcelRx Pharmaceuticals (ACRX), Alimera Sciences (ALIM), Novavax (NVAX) and BIOLINERX LTD/S (BLRX). Who are Eyepoint Pharmaceuticals' key executives? Eyepoint Pharmaceuticals' management team includes the folowing people: Ms. Nancy S. Lurker, Pres, CEO & Director (Age 62)Mr. Leonard S. Ross, VP of Fin. & Chief Accounting Officer (Age 69)Dr. Dario A. Paggiarino, VP & Chief Medical Officer (Age 62)Mr. David J. Price, Chief Financial Officer (Age 56)Mr. Marty Nazzaro, Sr. VP of Operations How do I buy shares of Eyepoint Pharmaceuticals? Shares of EYPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Eyepoint Pharmaceuticals' stock price today? One share of EYPT stock can currently be purchased for approximately $1.70. How big of a company is Eyepoint Pharmaceuticals? Eyepoint Pharmaceuticals has a market capitalization of $183.80 million and generates $2.96 million in revenue each year. The company earns $-53,170,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Eyepoint Pharmaceuticals employs 55 workers across the globe.View Additional Information About Eyepoint Pharmaceuticals. What is Eyepoint Pharmaceuticals' official website? The official website for Eyepoint Pharmaceuticals is http://eyepointpharma.com/. How can I contact Eyepoint Pharmaceuticals? Eyepoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The company can be reached via phone at 833-393-7646 or via email at [email protected] MarketBeat Community Rating for Eyepoint Pharmaceuticals (NASDAQ EYPT)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 378 (Vote Outperform)Underperform Votes: 302 (Vote Underperform)Total Votes: 680MarketBeat's community ratings are surveys of what our community members think about Eyepoint Pharmaceuticals and other stocks. Vote "Outperform" if you believe EYPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYPT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/20/2020 by MarketBeat.com StaffFeatured Article: What are the benefits of a balanced fund?
